Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 A way forward on the medically appropriate use of white cell growth factors.

× No keyword cloud information.

46 in total

Review 1. Systematic review of efficacy of dose-dense versus non-dose-dense chemotherapy in breast cancer, non-Hodgkin lymphoma, and non-small cell lung cancer.

Authors: Gary H Lyman; Richard L Barron; Jaime L Natoli; Ross M Miller
Journal: Crit Rev Oncol Hematol Date: 2011-06-01 Impact factor: 6.312

2. Comparison of survival and quality of life in advanced non-small-cell lung cancer patients treated with two dose levels of paclitaxel combined with cisplatin versus etoposide with cisplatin: results of an Eastern Cooperative Oncology Group trial.

Authors: P Bonomi; K Kim; D Fairclough; D Cella; J Kugler; E Rowinsky; M Jiroutek; D Johnson
Journal: J Clin Oncol Date: 2000-02 Impact factor: 44.544

3. 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline.

Authors: Thomas J Smith; James Khatcheressian; Gary H Lyman; Howard Ozer; James O Armitage; Lodovico Balducci; Charles L Bennett; Scott B Cantor; Jeffrey Crawford; Scott J Cross; George Demetri; Christopher E Desch; Philip A Pizzo; Charles A Schiffer; Lee Schwartzberg; Mark R Somerfield; George Somlo; James C Wade; James L Wade; Rodger J Winn; Antoinette J Wozniak; Antonio C Wolff
Journal: J Clin Oncol Date: 2006-05-08 Impact factor: 44.544

4. A randomized, crossover comparison of standard-dose versus low-dose lenograstim in the prophylaxis of post-chemotherapy neutropenia.

Authors: O Juan; J M Campos; V Carañana; J J Sanchez; R Casañ; V Alberola
Journal: Support Care Cancer Date: 2001-06 Impact factor: 3.603

5. Limits on Medicare's ability to control rising spending on cancer drugs.

Authors: Peter B Bach
Journal: N Engl J Med Date: 2009-01-27 Impact factor: 91.245

6. Use of colony-stimulating factors with chemotherapy: opportunities for cost savings and improved outcomes.

Authors: Arnold L Potosky; Jennifer L Malin; Benjamin Kim; Elizabeth A Chrischilles; Solomon B Makgoeng; Nadia Howlader; Jane C Weeks
Journal: J Natl Cancer Inst Date: 2011-06-13 Impact factor: 13.506

7. Acute myeloid leukemia and myelodysplastic syndrome after doxorubicin-cyclophosphamide adjuvant therapy for operable breast cancer: the National Surgical Adjuvant Breast and Bowel Project Experience.

Authors: Roy E Smith; John Bryant; Arthur DeCillis; Stewart Anderson
Journal: J Clin Oncol Date: 2003-04-01 Impact factor: 44.544

8. Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer.

Authors: Donald A Berry; Constance Cirrincione; I Craig Henderson; Marc L Citron; Daniel R Budman; Lori J Goldstein; Silvana Martino; Edith A Perez; Hyman B Muss; Larry Norton; Clifford Hudis; Eric P Winer
Journal: JAMA Date: 2006-04-12 Impact factor: 56.272

9. Recombinant granulocyte colony stimulating factor reduces the infectious complications of cytotoxic chemotherapy.

Authors: V Trillet-Lenoir; J Green; C Manegold; J Von Pawel; U Gatzemeier; B Lebeau; A Depierre; P Johnson; G Decoster; D Tomita
Journal: Eur J Cancer Date: 1993 Impact factor: 9.162

10. Outcomes of cancer treatment for technology assessment and cancer treatment guidelines. American Society of Clinical Oncology.

Authors:
Journal: J Clin Oncol Date: 1996-02 Impact factor: 44.544

4 in total

1. Practice Patterns for Older Adult Patients With Advanced Cancer: Physician Office Versus Hospital Outpatient Setting.

Authors: Allison Lipitz-Snyderman; Coral L Atoria; Stephen M Schleicher; Peter B Bach; Katherine S Panageas
Journal: J Oncol Pract Date: 2018-12-13 Impact factor: 3.840

2. Adherence to granulocyte-colony stimulating factor (G-CSF) guidelines to reduce the incidence of febrile neutropenia after chemotherapy--a representative sample survey in Germany.

Authors: Hartmut Link; J Nietsch; M Kerkmann; P Ortner
Journal: Support Care Cancer Date: 2015-06-17 Impact factor: 3.603

3. Risk and consequences of chemotherapy-induced neutropenic complications in patients receiving daily filgrastim: the importance of duration of prophylaxis.

Authors: Derek Weycker; Rich Barron; John Edelsberg; Alex Kartashov; Jason Legg; Andrew G Glass
Journal: BMC Health Serv Res Date: 2014-04-27 Impact factor: 2.655

4. Patterns of granulocyte colony-stimulating factor prophylaxis in patients with cancer receiving myelosuppressive chemotherapy.

Authors: Prasad L Gawade; Shuling Li; David Henry; Nancy Smith; Rajesh Belani; Michael A Kelsh; Brian D Bradbury
Journal: Support Care Cancer Date: 2020-01-10 Impact factor: 3.603

4 in total